Date: 2017-05-02
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the Combined Otolaryngology Spring Meetings (COSM)
Company: Sensorion (France)
Product: SENS-401
Action
mechanism:
- setron/selective-5-ht3-receptor-antagonist. R-azasetron besylate aims to protect and preserve inner ear tissue when lesions are present that can cause progressive or sequelar hearing impediments. It is one of the two enantiomer forms of SENS-218, azasetron, a racemic molecule belonging to the family of setrons marketed in Asia under the name Serotone.
Disease: prevention of cisplatin-induced ototoxicity
Therapeutic
area: Otorhinolaryngology
Country:
Trial
details:
Latest
news:
- • On May 2, 2017, Sensorion announced that it presented preclinical results for SENS-401 in the prevention of cisplatin-induced ototoxicity during a podium presentation at the Combined Otolaryngology Spring Meetings (COSM). The study consisted of an in vivo animal model that was orally administered SENS-401 immediately prior to, and for 14 days following, the intravenous infusion of cisplatin. In this study, Sensorion evaluated the preventive activity of SENS-401 on cisplatin toxicity.
The three doses of SENS-401 that were evaluated (6.6, 13.2 and 26.4 mg/kg/day) demonstrated statistically significant activity compared to the placebo:
- an elevation of auditory brainstem response (ABR) thresholds of between 10 and 30 dB
- - an improvement in distortion product otoacoustic emission (DPOAE) amplitudes of between 10 and 20 dB
- - significantly higher survival rate for sensorineural hair cells in the treated group.
Sensorion intends to continue pre-clinical development of SENS-401 on our screening platform in order to evaluate the opportunity of developing this drug in this new indication.
Is
general: Yes
